Switzerland-based ADC Therapeutics SA has appointed Ameet Mallik as its new chief executive to succeed Chris Martin who will become a non-executive member of the board of directors. Mr Mallik will be based in the US. He was most recently CEO of Rafael Holdings, a biotech company focused on developing oncology and immune therapies. Previously, he spent 16 years at Novartis where he held successive executive positions in oncology. Mr Mallik holds an MBA from the Wharton School at the University of Pennsylvania, US.
ADC Therapeutics announced the appointment on 9 May 2022.
Copyright 2022 Evernow Publishing Ltd